TCGA-DQ-5624-01A-01R-1873-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.570
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- ANGIOGENESIS+0.540
- TGF_BETA_SIGNALING+0.530
- MYOGENESIS+0.510
- HYPOXIA+0.430
- UV_RESPONSE_DN+0.410
- APOPTOSIS+0.360
- PROTEIN_SECRETION+0.360
- COAGULATION+0.350
Top 10 suppressed
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.530
- MYC_TARGETS_V1-0.410
- MYC_TARGETS_V2-0.300
- OXIDATIVE_PHOSPHORYLATION-0.260
- SPERMATOGENESIS-0.240
- DNA_REPAIR-0.230
- INTERFERON_ALPHA_RESPONSE-0.180
- BILE_ACID_METABOLISM-0.140
- FATTY_ACID_METABOLISM-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-K4-A4AB-01B-12R-A28M-07 | — | — | 0.921 |
| 2 | TCGA-A2-A0EO-01A-11R-A034-07 | — | A | 0.907 |
| 3 | TCGA-CV-5970-01A-11R-1686-07 | — | — | 0.900 |
| 4 | 20030015.LumB | — | A | 0.900 |
| 5 | TCGA-E2-A153-01A-12R-A12D-07 | — | A | 0.898 |
| 6 | SRR25617877 | — | A | 0.889 |
| 7 | 6b548699-9440-4acc-86b6-faeb367454a2 | — | — | 0.885 |
| 8 | TCGA-BA-5557-01A-01R-1514-07 | — | — | 0.885 |
| 9 | TCGA-CR-6474-01A-11R-1873-07 | — | — | 0.885 |
| 10 | 22620634-aa34-4cb5-a37f-5a7b0c47cd0e | — | — | 0.878 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.570 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.540 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.530 | Inavolisib | — uncovered |
| MYOGENESIS | 0.510 | Inavolisib | — uncovered |
| HYPOXIA | 0.430 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.410 | Inavolisib | — uncovered |
| APOPTOSIS | 0.360 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.330 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.270 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |